Revolution Medicines stock reiterated at Buy by Stifel, $230 target
Stifel reiterated a Buy rating on Revolution Medicines (RVMD) with a $230 price target, citing near-term buying opportunities and potential upside beyond PDAC. The stock has gained 215% over the past year. The company reported $197.6M in Q3 2026 product sales, though it posted a net loss of $407.5M due to increased spending.
How this was made
The 30-second read
Why it matters
The analyst upgrade adds a fresh catalyst that could attract new capital into the stock, especially after the after‑hours price move.
Market read
The new rating provides a concrete, time‑sensitive decision point for traders, potentially driving short‑term upside.
What to watch
Potential regulatory setbacks or competition in the PDAC space could limit upside.
Background
Revolution Medicines recently reported its first quarter product revenue after FDA approval, but posted a sizable net loss.
Ticker impact
Stifel reiterated a Buy rating on Revolution Medicines with a $230 price target and noted after‑hours share uplift.
upward pressure as investors price in the new target and near‑term upside thesis
Buy rating and $230 target represent a fresh, material upgrade for a biotech with recent revenue ramp, prompting short‑term buying.
Market effects
Boosts sentiment for small‑cap biotech sector as analysts signal confidence in early commercial revenue.
Limited to US biotech equities; no broader regional effect.
Minor, confined to investors tracking biotech pipelines.
Counterpoint
The rating may be premature given the company's ongoing net loss and high cash burn.
Key entities
- companyRevolution Medicines
Biotech firm developing PDAC therapies.
- analystStifel
Investment bank providing the Buy rating and $230 target.
